Browsing Tag
Allay Therapeutics
3 posts
Can ATX101 disrupt the multibillion-dollar post-surgical pain market?
Can Allay Therapeutics’ ATX101 replace opioids in post-surgical care? Read how this long-acting bupivacaine platform may disrupt the pain relief market by 2026.
Non-opioid pain drugs in 2025: Top clinical-stage biotechs to watch
Explore the top biotech companies leading the charge in non-opioid pain relief in 2025, from Allay Therapeutics to Vertex Pharmaceuticals.
Allay Therapeutics raises $57.5m to advance ATX101 non-opioid pain therapy in knee surgery
Allay Therapeutics raises $57.5M to advance ATX101 pain therapy in U.S. knee surgery trial, with FDA backing and growing Asia partnerships.